All News
What Lies Beneath: Understanding Nailfold Capillaroscopy
Capillaroscopy is a non-invasive imaging technique used for the in vivo assessment of the microcirculation. kin capillaries at the nailfold are evaluated because the fingers are involved in pathological processes such as Raynaud’s phenomenon. Several abstracts and sessions on nailfold capillaroscopy were presented during ACR24.
Read Article
Assessment of axSpA
Dr. Antoni Chan reviews abstracts 0818 and 0819, presented at #ACR24.
https://t.co/2qI6DnnflP https://t.co/BuTdnlMfxq
Dr. John Cush RheumNow ( View Tweet)
PsA Ultrasound Updates
Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR24.
https://t.co/DZBe8uNpJS https://t.co/wIS1hUZnAS
Dr. John Cush RheumNow ( View Tweet)
#ACR Best 2024 - Day 4
Although the last day of #ACR24 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today. As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.… https://t.co/ws9BOxkZft https://t.co/trMevuvvyX
Dr. John Cush RheumNow ( View Tweet)
Methotrexate to Prevent RA, Clear as Mud
Intervention in individuals predisposed to rheumatoid arthritis (RA), aiming for prevention, is a significant topic. Seropositivity for rheumatoid factor and ACPA can precede RA by years. Some patients experience a pre-RA arthralgia… https://t.co/D51CoZAzce https://t.co/lgZalnDeb3
Dr. John Cush RheumNow ( View Tweet)
Predicting flares in rheumatic diseases with machine learning
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.… https://t.co/6oFRp0zyBw https://t.co/fcMrJOg4mM
Dr. John Cush RheumNow ( View Tweet)
Changing Mindsets about Methotrexate Side Effects
Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.
https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr
Dr. John Cush RheumNow ( View Tweet)
Say Goodbye to Methotrexate in PMR?
Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24
https://t.co/x662FbdNoR https://t.co/uvMPHpmRHZ
Dr. John Cush RheumNow ( View Tweet)
⏩Lecture by Prof Takeuchi on Sjogren Syndrome. Anti-centromere ab is seen in 10% of primary Sjogren syndrome. more likely to have sclerodactyly. https://t.co/mVry2OaNmq @IRACON24Blr https://t.co/SZlWQDpx8B
Links:
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
PsA Ultrasound Updates
Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR2024
https://t.co/XJOuKl8lCF https://t.co/XPMlf3sOnU
Dr. John Cush RheumNow ( View Tweet)
Day 1 Recap at #ACR24
Panelists Dr. Sheila Reyes, Dr. Adela Castro, Dr. Mike Putman and Dr. Jack Cush recap the most interesting abstracts and presentations they saw on day 1 of ACR 2024.
https://t.co/8M0WhOLETg https://t.co/hW5cgRiy6F
Dr. John Cush RheumNow ( View Tweet)
Assessing ASAS Criteria: CLASSIC Study Results
Dr. Adela Castro discusses abstract 0820, presented at #ACR24
https://t.co/rlzL8nAsiI https://t.co/7lbXWE3gdJ
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. Content is chosen by RheumNow & its facult.y
Dr. John Cush RheumNow ( View Tweet)
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at #ACR24
https://t.co/qkDuutgqvv https://t.co/Agqopk6bh2
Dr. John Cush RheumNow ( View Tweet)
SELECT-GCA: Efficacy and Safety of Upadacitinib
Dr. Richard Conway discusses abstract 0770, presented at #ACR24
https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe
Dr. John Cush RheumNow ( View Tweet)
Aging Gracefully in Managing Rheumatic Diseases
Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24.
https://t.co/tyT5d0JsEG https://t.co/szfDsSuWBx
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
A new score to quantify GCA inflammation?
The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. #ACR24… https://t.co/b5H7KOtZPC https://t.co/AvrwHcXI7r
Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA?
We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
Gender Differences in SpA
#ACR24 provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented… https://t.co/iEh0s3sIhc https://t.co/SRhz0Uwwwv
Dr. John Cush RheumNow ( View Tweet)
